Auris Medical Holding AG (NASDAQ:EARS) Q2 2020 Earnings Conference Call - Final Transcript
Sep 17, 2020 • 08:30 am ET
Thank you. [Operator Instructions] We do have one question now, and it comes from the line of Max Jacobs from Edison Group. Please ask your question.
Hi, guys. Thanks for taking my question. So first I just wanted to ask about AM-301, like, how long would that gel coating last? Was it -- is it just meant for like short-term use?
Hi, Max. Well, this is a -- obviously, a very important question. So as we know, within the nose, you have those tiny little cilia that constantly remove objects, particles from the nose. And so that's a fairly quick process. Now, one of the particularities here of this gel formulation is that it's actually quite sticky. So it's a thin film, but it's designed to stay to remain here for an extended period of time. So we are estimating that it will be up to a few hours, but we will need to perform here some additional experiments. But in any case, it's definitely more than the -- let's say, natural residence time within the nose.
Okay. Great. And then, since you are targeting the over-the-counter pathway, I was just wondering if you have any idea as to what the price might be?
Well, we do have some ideas about the potential pricing. I think we want to make this clearly an affordable product. On the other hand, it's a little bit premature here to already talk about the pricing. I mean, it is a consumer health product, so it's a classic nasal spray. And here was one spray, you may have enough supplies here to cover, for example, 14 days or one month, something like that. But that's still under consideration and while we expect in any case that it will become something that is affordable and effective and safe.
Okay. Great. And then, it doesn't interfere with, I mean, it will still be reasonable through the nose, like, you wouldn't expect much discomfort from the use of this gel?
Absolutely. I mean, this one of the key requirements here. And as I said, this is a very thin film that is established. And so therefore breathing, this should be absolutely normal. I mean, this is one of the advantages, obviously. We know that some people are unable to wear face masks for various reasons. Some people don't like wearing masks. So in a sense, what we want to achieve here is really reinforce the first line of defense of the nasal mucosa by adding here a protective layer and in addition also binding or trapping these particles and helping to remove them. So it's kind of a dual action.
Okay. Great. And then just moving to the Phase II TRAVERS trial data. I was wondering if you could just discuss like the clinical significance of, I guess it was like a little more than a 6-second benefit on the Standing on Foam tests, and then a 3-second benefit on the Tandem Romberg?
Yes. Okay. So we have here